The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2024

Filed:

Jun. 22, 2021
Applicant:

Arvinas Operations, Inc., New Haven, CT (US);

Inventors:

Andrew P. Crew, Chester, CT (US);

Lawrence B. Snyder, Killingworth, CT (US);

Jing Wang, Milford, CT (US);

Hanqing Dong, Madison, CT (US);

Yimin Qian, Plainsboro, NJ (US);

Michael Berlin, Flemington, NJ (US);

Assignee:

Arvinas Operations, Inc., New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/166 (2006.01); A61K 31/405 (2006.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); A61K 38/45 (2006.01); C12N 9/10 (2006.01); A61K 31/351 (2006.01); C07D 471/04 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 405/12 (2006.01); C07D 417/14 (2006.01); C07D 409/14 (2006.01); A61K 47/55 (2017.01);
U.S. Cl.
CPC ...
A61K 31/166 (2013.01); A61K 31/351 (2013.01); A61K 31/405 (2013.01); A61K 38/45 (2013.01); A61K 47/545 (2017.08); A61K 47/55 (2017.08); A61K 47/555 (2017.08); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C12N 9/1007 (2013.01); C12Y 201/01043 (2013.01);
Abstract

The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.


Find Patent Forward Citations

Loading…